Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan H Moy

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
NPJ Precision Oncology|July 17, 2025
Multi-omic characterization of early-onset esophagogastric cancerLawrence W Wu, Sachin Kumar Deshmukh, Sharon Wu, et al.
Immunity|December 31, 2013
Antiviral autophagy restrictsRift Valley fever virus infection and is conserved from flies to mammalsRyan H Moy, Beth Gold, Jerome M Molleston, et al.
Genes & Development|July 31, 2016
A conserved virus-induced cytoplasmic TRAMP-like complex recruits the exosome to target viral RNA for degradationJerome M Molleston, Leah R Sabin, Ryan H Moy, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2022
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinomaRyan H Moy, Megan Greally, Joanne F Chou, et al.
Blood|January 7, 2017
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxisRyan H Moy, Austin P Huffman, Lee P Richman, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2025
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)Anuradha Krishnamurthy, Hong Wang, John C Rhee, et al.
The Journal of Experimental Medicine|September 16, 2015
Epithelial-intrinsic IKKα expression regulates group 3 innate lymphoid cell responses and antibacterial immunityPaul R Giacomin, Ryan H Moy, Mario Noti, et al.
JCO Precision Oncology|February 9, 2022
Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived XenograftsRyan H Moy, Henry S Walch, Marissa Mattar, et al.
Cell Reports. Medicine|May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A Braun, Marcus S Noel, Ryan H Moy, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesisJin Qian, Chenkai Ma, Quin T Waterbury, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
NPJ Precision Oncology|July 17, 2025
Multi-omic characterization of early-onset esophagogastric cancerLawrence W Wu, Sachin Kumar Deshmukh, Sharon Wu, et al.
Immunity|December 31, 2013
Antiviral autophagy restrictsRift Valley fever virus infection and is conserved from flies to mammalsRyan H Moy, Beth Gold, Jerome M Molleston, et al.
Genes & Development|July 31, 2016
A conserved virus-induced cytoplasmic TRAMP-like complex recruits the exosome to target viral RNA for degradationJerome M Molleston, Leah R Sabin, Ryan H Moy, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2022
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinomaRyan H Moy, Megan Greally, Joanne F Chou, et al.
Blood|January 7, 2017
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxisRyan H Moy, Austin P Huffman, Lee P Richman, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2025
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)Anuradha Krishnamurthy, Hong Wang, John C Rhee, et al.
The Journal of Experimental Medicine|September 16, 2015
Epithelial-intrinsic IKKα expression regulates group 3 innate lymphoid cell responses and antibacterial immunityPaul R Giacomin, Ryan H Moy, Mario Noti, et al.
JCO Precision Oncology|February 9, 2022
Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived XenograftsRyan H Moy, Henry S Walch, Marissa Mattar, et al.
Cell Reports. Medicine|May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A Braun, Marcus S Noel, Ryan H Moy, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesisJin Qian, Chenkai Ma, Quin T Waterbury, et al.
Pageof 4